-
Mashup Score: 4Best of 2024: Vasculitis Pearls | RheumNow - 15 hour(s) ago
Once again RheumNow Live 2024 really delivered with high impact learning packed into short sessions. As someone with an interest in vasculitis it was fantastic to see four of my favorite speakers in the Vasculitis Mavens and STEP talks. They gave us what we really want from these talks – personal opinions and approaches that go beyond the guidelines. They really dropped a selection of pearls on us and I wanted to share a few of these with you.
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Best of 2024: Determinants of Gout Flares | RheumNow - 17 hour(s) ago
Approximately 12 million US adults in the US have gout. Two recent literature reports in JAMA and Arthritis Care & Research highlight contributors to gout flares.
Source: rheumnow.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers has found that nearly one in ten patients experiences opioid dependence or opioid use disorder and nearly one in three shows symptoms of dependence and opioid use disorder.
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 21
A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated. Multicentre study of 471 GCA patients treated with TCZ, assessed outcomes according to vascular phenotypes: a) cranial (cGCA), b) extracranial (ecGCA) and c) mixed (mixGCA). Outcomes included clinical remission, EULAR complete remission, relapses, absence of inflammation in imaging techniques, and safety.
Source: rheumnow.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0ICYMI: Are Emulation Trials a Fantasy? | RheumNow - 4 day(s) ago
Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4Home | RheumNow - 4 day(s) ago
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.
Source: rheumnow.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 11Outcome of Pain in Hand Osteoarthritis | RheumNow - 10 day(s) ago
Leiden cohort study of hand osteoarthritis (HOA) patients shows that over 4 years, pain outcomes are variable, and not inevitably worsening.A total of 356 HOA patients (83% female, mean 60 years) were enrolled from the Hand OSTeoArthritis in Secondary care (HOSTAS) cohort. Outcomes were assessed using annual Australian/Canadian hand osteoarthritis index (AUSCAN) pain subscale (range 0-20) measurements. Pain changes were categorized as deterioration, stable and improvement using the Minimal Clinical Important Improvement (MCII).
Source: rheumnow.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 4Treat-to-Target LLDAS in Lupus | RheumNow - 10 day(s) ago
Patients with highly active systemic lupus erythematosus (SLE) appeared to sustain much less organ damage and fewer disease flares when drug therapy yielded substantial relief, researchers found.Unfortunately, only a minority of such patients achieved low disease activity or remission in the multinational cohort study, according to Alberta Hoi, MBBS, PhD, of Monash University in Clayton, Australia, and colleagues.
Source: rheumnow.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 3ACR24 JAK TYK Topic Panel | RheumNow - 15 day(s) ago
Join us for an in-depth discussion about the ACR Annual Meeting! This expert panel will explore the latest research and clinical applications of JAK and TYK inhibitors in managing rheumatic diseases. Stay informed about the cutting-edge therapies shaping the future of rheumatology care. Dr. Janet Pope London, Ontario Dr. David Liew Melbourne Dr. Michael Putman Milwaukee
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 7Phase 2b Study of Ianalumab in Sjögren's | RheumNow - 16 day(s) ago
A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren’s disease (SjD).The Phase 2b trial enrolled 190 SjD patients who were randomized (1:1:1:1) to either placebo or ianalumab (5, 50, or 300 mg) given subcutaneously every 4 weeks in the initial 24 week treatment period [TP]1). At week 24, patients on 300 mg were re-randomized to either 300 mg or placebo till week 52 (TP2). The endpoint measures were (ESSDAI, ESSPRI, PaGA, and PhGA.
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet
Best of 2024: Vasculitis Pearls https://t.co/3gE4VvXkby https://t.co/8qDiuGOHMc